Tag : FR

Health

Sanofi to pay Lexicon $260 million for terminated partnership

headline
The logo of Sanofi is seen at the company’s research and production centre in Vitry-sur-Seine, France, August 6, 2019. REUTERS/Charles Platiau (HeadlineNews) – Lexicon Pharmaceuticals...
Health

Sanofi wins FDA approval to sell dengue shot in parts of U.S.

headline
FILE PHOTO: The Sanofi logo is seen at the company’s Sanofi Pasteur headquarters in Lyon, France, October 26, 2015. REUTERS/Robert Pratta CHICAGO (HeadlineNews) – The...
Health

FDA approves expanded label for Regeneron/Sanofi’s cholesterol drug

headline
(HeadlineNews) – The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc’s cholesterol drug Praluent as a treatment to cut the risk of...
Health

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

headline
(HeadlineNews) – The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with...
Health

Philippines to charge officials of Sanofi, government over dengue vaccine

headline
MANILA/PARIS (HeadlineNews) – The Philippine Department of Justice on Friday said it had found probable cause to indict officials from French drugmaker Sanofi and former...
Health

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

headline
NEW YORK (HeadlineNews) – Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but...
Health

FDA advisory panel split over Sanofi-Lexicon diabetes drug

headline
(HeadlineNews) – An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1...
Health

Sanofi drug Dupixent wins FDA approval to treat asthma

headline
(Reuters) – France’s Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More